{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-019520","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2026-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.289291+00:00","generated_at":"2026-05-16T08:52:42.792264+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones","bullets":["Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.","Janux responsible for preclinical through IND; BMS handles later development and commercialization.","Tiered royalties on global net sales: high-single to low-double digit percentages.","Collaboration validates Janux's TRACTr/TRACIr/ARM platforms for solid tumor oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-019520","json":"https://secwatch.observer/filing/0001193125-26-019520.json","markdown":"https://secwatch.observer/filing/0001193125-26-019520.md","text":"https://secwatch.observer/filing/0001193125-26-019520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/0001193125-26-019520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/janx-20260121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:52:42.792264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9b82bb7b816fe9a46716a2cd5c2fe000ba0ac57","claim":"Janux Therapeutics, Inc. entered into Collaboration Agreement with Bristol-Myers Squibb Company valued at upfront payment of $15 million (effective 2026-01-21).","evidence_excerpt":"On January 21, 2026, Janux Therapeutics, Inc. (“Janux” or the “Company”) and Bristol-Myers Squibb Company (“BMS”) entered into an exclusive license and collaboration agreement (the “Collaboration Agreement”) to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types (the “Collaboration Target”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526019520/0001193125-26-019520-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Value","value":"upfront payment of $15 million"},{"label":"Effective","value":"2026-01-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}